☰

Alessio Ciulli

Affiliations: 
University of Dundee, Dundee, Scotland, United Kingdom 
Area:
chemical biology, biochemistry, structural biology, PROTACs, targeted protein degradation, fragment-based drug design
Google:
"Alessio Ciulli"
Mean distance: (not calculated yet)
 
Tree Publications Similar researchers PubMed Report error

Parents

Sign in to add mentor
Ivano Bertini research assistant 2000-2002 University of Florence
Christopher Abell grad student 2002-2006 University of Cambridge, United Kingdom
 (Gates Cambridge Scholar, BBSRC CASE with Astex Therapeutics)
Christopher Abell post-doc 2006-2009 University of Cambridge, United Kingdom
 (College Junior Research Fellow)
Tom Blundell post-doc 2006-2009 University of Cambridge, United Kingdom (Computational Biology Tree)
 (College Junior Research Fellow)
Craig M. Crews post-doc 2009-2009 Yale
 (HFSP Visiting Fellow)

Children

Sign in to add trainee
Emil Bulatov grad student 2010-2014 University of Dundee
Fleur M. Ferguson grad student 2010-2014 University of Cambridge, United Kingdom
Dylan M. Lynch post-doc 2022- University of Dundee
Matthias Baud post-doc 2011-2013 University of Dundee
Carles Galdeano post-doc 2012-2015 University of Dundee
Morgan Gadd post-doc 2013-2016 University of Dundee

Collaborators

Sign in to add collaborator
BETA: Related publications

Publications

You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect.

Kofink C, Trainor N, Mair B, et al. (2022) A selective and orally bioavailable VHL-recruiting PROTAC achieves SMARCA2 degradation in vivo. Nature Communications. 13: 5969
Liu X, Kalogeropulou AF, Domingos S, et al. (2022) Discovery of XL01126: A Potent, Fast, Cooperative, Selective, Orally Bioavailable, and Blood-Brain Barrier Penetrant PROTAC Degrader of Leucine-Rich Repeat Kinase 2. Journal of the American Chemical Society
Diehl CJ, Ciulli A. (2022) Discovery of small molecule ligands for the von Hippel-Lindau (VHL) E3 ligase and their use as inhibitors and PROTAC degraders. Chemical Society Reviews
Grohmann C, Magtoto CM, Walker JR, et al. (2022) Development of NanoLuc-targeting protein degraders and a universal reporter system to benchmark tag-targeted degradation platforms. Nature Communications. 13: 2073
Cowan AD, Ciulli A. (2022) Driving E3 Ligase Substrate Specificity for Targeted Protein Degradation: Lessons from Nature and the Laboratory. Annual Review of Biochemistry
Webb T, Craigon C, Ciulli A. (2022) Targeting epigenetic modulators using PROTAC degraders: Current status and future perspective. Bioorganic & Medicinal Chemistry Letters. 63: 128653
Tarantelli C, Cannas E, Ekeh H, et al. (2021) The bromodomain and extra-terminal domain degrader MZ1 exhibits preclinical anti-tumoral activity in diffuse large B-cell lymphoma of the activated B cell-like type. Exploration of Targeted Anti-Tumor Therapy. 2: 586-601
Müller S, Ackloo S, Al Chawaf A, et al. (2021) Target 2035 - update on the quest for a probe for every protein. Rsc Medicinal Chemistry. 13: 13-21
Laveglia V, Giachetti A, Cerofolini L, et al. (2021) Automated Determination of Nuclear Magnetic Resonance Chemical Shift Perturbations in Ligand Screening Experiments: The PICASSO Web Server. Journal of Chemical Information and Modeling. 61: 5726-5733
Imaide S, Riching KM, Makukhin N, et al. (2021) Trivalent PROTACs enhance protein degradation via combined avidity and cooperativity. Nature Chemical Biology. 17: 1157-1167
See more...